Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944, Encoding for an Anti-Chikungunya Virus Monoclonal Antibody, in Healthy Adults

Trial Profile

A Phase 1, Randomized, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944, Encoding for an Anti-Chikungunya Virus Monoclonal Antibody, in Healthy Adults

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 12 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MRNA-1944 (Primary)
  • Indications Chikungunya virus infections
  • Focus Adverse reactions; First in man
  • Sponsors Moderna Therapeutics
  • Most Recent Events

    • 12 May 2020 Status changed from recruiting to suspended.
    • 07 May 2020 According to a Moderna Therapeutics media release, enrollment in this trial has been paused by the site due to the impact of COVID-19.
    • 12 Jan 2020 According to a Moderna Therapeutics media release, dosing of the cohort at 0.6 mg/kg with steroid premedication has begun.Dosing of an additional cohort with two doses of 0.3 mg/kg (without steroid premedication) given one week apart is expected.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top